| Trial ID: | L2891 |
| Source ID: | NCT00525889
|
| Associated Drug: |
Il-2
|
| Title: |
Proleukin and Rapamune in Type 1 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 1
|
| Interventions: |
DRUG: IL-2|DRUG: Rapamycin
|
| Outcome Measures: |
Primary: Incidence and severity of adverse events and laboratory anomalies, through day 364 | Secondary: AUC for C-peptide responses following MMTT, various|Frequency of severe hypoglycemia, various|Insulin dose in units per kilogram, various|HbA1c levels, various
|
| Sponsor/Collaborators: |
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Collaborators: Immune Tolerance Network (ITN)
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
9
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2007-08
|
| Completion Date: |
2013-09
|
| Results First Posted: |
|
| Last Update Posted: |
2017-02-08
|
| Locations: |
Naomi Berrie Diabetes Center, Columbia University, New York, New York, 10032, United States|Oregon Health Sciences University, Portland, Oregon, 97239, United States|Benaroya Research Institute, Seattle, Washington, 98101, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00525889
|
